Small molecules
Small molecules that activate or enhance reelin pathway signaling
About us
Building Medicines Around the Biology of Reelin
Avendia Therapeutics was founded on decades of research demonstrating the central role of reelin in brain development, synaptic function, plasticity, and cognition.
Our founders bring complementary expertise in reelin biology, neuroscience, drug discovery, and CNS therapeutic development. Together, we are translating a deep understanding of reelin signaling into a pipeline of potential medicines for neurological and neuropsychiatric disorders.
Our approach
A reelin-focused therapeutic platform
We believe reelin represents an unusually compelling therapeutic opportunity because it regulates multiple interconnected mechanisms required for healthy synaptic function.
Avendia is building a reelin-focused therapeutic platform spanning small-molecule and gene therapy approaches to enhance or restore this biology. Our programs are designed around the needs of each disease rather than a single therapeutic modality.
This approach allows us to pursue reelin biology through:
Gene therapies
Gene therapies designed to provide sustained reelin activity in targeted brain regions
Our mission
To translate the biology of reelin into transformative medicines that restore brain function and improve the lives of patients and families affected by neurological disease.
The team
Deep expertise, focused on translation
Co-Founder & CEO
Jennifer Daily, PhD
Nearly 2 decades of gene therapy experience. Successfully led multiple neurological gene therapy programs from discovery through first-in-human trials.
Co-Founder & CSO
Edwin Weeber, PhD
Accomplished researcher with successful academic and industry career. Deep expertise in understanding and treating neurological disorders, and inventor of the reelin technology.
One biology, multiple opportunities